CP7 Control Synthetic Peptide

• Reactivity: Hu
• Applications: Func
• Concentration: LYOPH

CP7 Control Synthetic Peptide Summary

• Description: A peptide to CP7 Control.

  Amino Acid Sequence: RNTISGNIYSARRRRRRRRR
  
  Inhibitor Content: CP7, Control Peptide: 1 mg (lyophilized) RNTISGNIYSARRRRRRRRR (Control sequence: RNTISGNIYSA). Molecular weight: 2601
  
  Inhibitor Family: TLR
  Inhibitor Target: TLR4
  Inhibitor Type: Inhibitor Peptide Set

• Preparation Method: Preparation of 5 mM CP7 Stock Solution
  Note: Bring the peptide to room temperature and quick spin the tubes before opening the caps.
  
  CP7: A final volume of 76 ul will make a 5 mM stock solution. Add 76 ul sterile H20 to the tube of peptide. Carefully pipet to ensure all of the peptide is dissolved.
  
  The stock solution may be diluted further to make working solutions. Dilute according to the needs for your assay. For example dilute 5 mM stock solutions 1:10 in sterile 1X PBS or cell culture media to make 500 uM working solutions. Working solutions should be made fresh daily and not stored.
• Source: Synthetic
• Content: CP7, Control Peptide: 1 mg (lyophilized) RNTISGNIYSARRRRRRRRR (Control sequence: RNTISGNIYSA). Molecular weight: 2601
• Protein/Peptide Type: Synthetic Peptide
• Purity: >95%, by HPLC.

Applications/Dilutions

• Dilutions:
  • In vitro assay

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Concentration: LYOPH
• Purity: >95%, by HPLC.
• Reconstitution Instructions: Please contact technical support for detailed reconstitution instructions.

Background

VIPER is a TLR4 specific inhibitory peptide that potently inhibits TLR4-mediated responses and is inert towards other TLR pathways (Bowie et al, 2010; Lysakova-Devine et al, 2010) . The TLR4 inhibitor consists of an 11 amino acid (KYSFKLILAEY) inhibitory sequence, derived from the A46 vaccinia virus protein, linked to a 9R (RRRRRRRRR) homopolymer delivery sequence.

CP7 is an inert control peptide. The control consists of an 11 amino acid (RNTISGNIYSA) inert sequence also linked to a 9R homopolymer delivery sequence. The 9R sequence efficiently delivers the peptides into cells. CP7 is designed to be a negative control peptide for inhibitory assays.

We note that this inhibitor is the first viral inhibitory peptide identified that is specific for a particular TLR pathway. Inhibition of TLR4 within the context of the overall TLR signaling network is illustrated in Figure 2. VIPER should be useful for elucidating new mechanisms and molecular interactions involved in TLR4 signaling, and may also have potential for leading to the development of a new class of novel therapeutics that perturb TLR4 signaling by targeting Mal and TRAM TIR domains. The identification of additional short virally derived peptides that perturb TLR signaling is sure to open a new era in knowledge about how viruses specifically interact with host immune systems.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Publications for CP7 Control Protein (NBP2-31231)(1)

Publication using NBP2-31231

• Mempin M, Hu H, Vickery K et al. Gram-Negative Bacterial Lipopolysaccharide Promotes Tumor Cell Proliferation in Breast Implant-Associated Anaplastic Large-Cell Lymphoma Cancers (Basel) 2021-10-22 [PMID: 34771464] (ELISA, Functional Assay)